Apligraf 300mg Injection contains the active constituent filgrastim. It is a white blood cell growth factor (granulocyte-colony stimulating factor) approved by the FDA to decrease the risk of developing febrile neutropenia ( occurrence of fever or infection associated with low WBC count) and to reduce the duration of neutropenia (low white blood cell count) in people who have non-myeloid cancer and are receiving chemotherapy drugs. It is also used to increase the number of WBC and decrease the length of time of fever in people with acute myeloid leukemia. It is also used in people undergoing bone marrow transplants and in people with severe chronic neutropenia (low number of neutrophils in the blood). Apligraf 300mg Injection is also used to prepare the blood for leukapheresis (a treatment in which certain blood cells are removed from the blood). It is also indicated to increase the chance of survival in people exposed to harmful amounts of radiation, which can cause severe damage to the bone marrow. Other uses include patients with advanced HIV infection, which will help to reduce the risk of infections. Apligraf 300mg Injection belongs to the class of medications called colony-stimulating factors. They work by helping the body to produce more White blood cells. WBCs are important because they help your body fight infection. These cells are highly sensitive to the effects of chemotherapy, which might cause a decrease in the number. If your WBC decreases, your body may not have enough cells to combat bacteria, putting you at risk of infection. Inform your physician if you have or have had liver disease, kidney problems, sickle cell anemia, or bone disease. Common side effects include fever, pain, rash, cough, shortness of breath, and nosebleeds.